Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan/Merck KGaA To Divest Five Generic Drugs To Clear Antitrust Hurdle For Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Amneal Pharmaceuticals is the beneficiary of FTC’s concerns about the sales power of the newly combined entity.

You may also be interested in...



Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products

The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.

Generic Paxil CR Will Launch By October 2008 Under GSK/Mylan Settlement

Mylan gains rights to market extended-release paroxetine in 12.5 mg, 25 mg and 37.5 mg doses.

Generic Paxil CR Will Launch By October 2008 Under GSK/Mylan Settlement

Mylan gains rights to market extended-release paroxetine in 12.5 mg, 25 mg and 37.5 mg doses.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel